Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

NCT04745832 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

82

Enrollment

INDUSTRY

Sponsor class

Stopped Discontinuation of zandelisib program

Conditions

Follicular Lymphoma (FL)
Non Hodgkin Lymphoma
Marginal Zone Lymphoma

Interventions

DRUG: Zandelisib
DRUG: Rituximab
DRUG: Bendamustine
DRUG: CHOP

Sponsor

MEI Pharma, Inc.

Collaborators

[object Object]